The New Standard in Breast Cancer-Related Lymphedema Risk Management

Abstract

For decades, Breast cancer-related lymphedema (BCRL) management has relied on conservative precautions like avoiding ipsilateral blood draws and blood pressure measurements despite limited empirical evidence. These restrictions may contribute to unintended consequences on the psychosocial well-being of survivors. Recent data indicates that nearly 73% of patients fear lymphedema, and those diagnosed with BCRL show significantly higher rates of antidepressant use and movement avoidance.

This paper reviews the shift from historical restrictions to evidence-based risk reduction strategies. It highlights evidence-based recommendations from the 2023 summit convened by the American Cancer Society and the Lymphology Association of North America, which align with updated international guidelines from organizations in the United Kingdom and Japan.
Current evidence supports a transition toward a prospective surveillance model, which emphasizes shared responsibility between patient and provider for early symptom detection. Key updates include the removal of universal restrictions on ipsilateral medical procedures and prophylactic compression during air travel for at-risk patients, provided no BCRL symptoms are present. Institutional implementation of these relaxed protocols has demonstrated that such changes are safe and do not increase BCRL incidence.

Aligning clinical practice with modern, evidence-based guidelines reduces the psycho-emotional burden on survivors by eliminating unnecessary lifestyle limitations. By prioritizing tailored risk assessment and longitudinal metrics that include mental health, clinicians can balance effective risk reduction with improved quality of life. Professional organizations and institutions are urged to adopt these updated standards to foster a more resilient recovery for breast cancer survivors.